

| | | |
|---|--------------------------------------|--------------------------|
| Form PTO 1449 US Department of Commerce Patents and Trademark Office JUL 24 2002 | ATTY DOCKET NO: P-BU 5149 | SERIAL NO. 10/079,929 |
| | APPLICANT: Sperandio and Bredesen | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | FILING DATE: February 19, 2002 | GROUP: 1614 |

U.S. PATENT DOCUMENTS

| EXAM. INITIALS | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
|-------------------|--------------------|------|------|-------|---------------|----------------|
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAM. INITIALS | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION (YES/NO) |
|-------------------|--------------------|------|---------|-------|---------------|-------------------------|
| | | | | | | |
| | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

| | | |
|-----|-------|---|
| DCG | n/i/a | Dal Canto and Gurney, "Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis," <u>American Journal of Pathology</u> 145:1271-1279 (1994) |
| DCG | 11 | Hongo et al., "Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristylated COOH terminus of the insulin-like growth factor I receptor," <u>Cancer Research</u> 58:2477-2484 (1998) |
| DCG | 1 | Liu et al., "Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells," <u>Cancer Research</u> 58:570-576 (1998) |

| | |
|-------------------------------------|-------------------------------|
| EXAMINER <i>Donald C. Gurney</i> | DATE CONSIDERED 12/01/2004 |
|-------------------------------------|-------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

JUL 26 2002

TECH CENTER 1600/2900

| | | |
|--|--|--------------------------|
| Form PTO 1449 US Department of Commerce Patent and Trademark Office JUL 24 2002 | ATTY DOCKET NO: P-BU 5149 APPLICANT: Sperandio and Bredesen | SERIAL NO. 10/079,929 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | FILING DATE: February 19, 2002 | GROUP: 1614 |

| | | |
|-----|---------|---|
| PCG | 11/1/04 | Liu et al., "Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)," <u>Cell</u> 75:59-72 (1993) |
| | | Plymate et al., "Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis," <u>Endocrine</u> 7:119-124 (1997) |
| | | Sperandio et al., "An alternative, nonapoptotic form of programmed cell death," <u>Proc. Natl. Acad. Sci. USA</u> 97:14376-14381 (2000) |
| | | Tennant et al., "Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium," <u>J. Clin. Endocrinol. Metab.</u> 81:3774-3782 (1996) |
| | | Turmaine et al., "Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease," <u>Proc. Natl. Acad. Sci. USA</u> 97:8093-8097 (2000) |

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

JUL 26 2002

TECH CENTER 1600.2

| | |
|--------------------------------------|-------------------------------------|
| EXAMINER <i>Daniel C. Barnett</i> | DATE CONSIDERED <i>11/1/2004</i> |
|--------------------------------------|-------------------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.